Patents Assigned to Endeavor Biomedicines, Inc.
  • Patent number: 11628167
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 18, 2023
    Assignee: Endeavor Biomedicines, Inc.
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco